The aim of study was to develop and validate two simple, sensitive, and extraction-free spectrophotometric methods for the estimation of risperidone in both pure and pharmaceutical preparations. They are based on the charge transfer complexation reactions between risperidone (RSP) as n-electron donor and p-chloranilic acid (p-CA) in method A and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in method B as π-acceptors. In method A, RSP reacts with p-CA in methanol to produce a bright pink-colored chromogen measured at 530?nm whereas, in method B, RSP reacts with DDQ in dichloromethane to form orange-colored complex with a maximum absorption at 460?nm. Beer's law was obeyed in the concentration range of 0–25 and 0–50?μg/mL with molar absorptivity of and L/moL/cm for RSP in methods A and B, respectively. The effects of variables such as reagents, time, and stability of the charge transfer complexes were investigated to optimize the procedures. The proposed methods have been successfully applied to the determination of RSP in pharmaceutical formulations. Results indicate that the methods are accurate, precise, and reproducible (relative standard deviation %). 1. Introduction Risperidone(RSP)chemicallyknownas4-[2-[4-(6-fluorobenzo[d]isoxazole-3-yl)-1-piperidyl]ethyl]-3-methyl-2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one??(Figure??1), is the atypical antipsychotic drug with a relatively low incidence of extra pyramidal side effects. It is used for the treatment of schizophrenia, bipolar disorder, and behavior problems in people with autism. In 2003, the FDA-approved RSP for the short-term treatment of the mixed and manic states associated with bipolar disorder. It is also approved for the treatment of irritability in children and adolescents with autism in 2006. The drug is officially included in 2005 European Pharmacopeia, and the official method of its determination is high-performance liquid chromatography [1]. Figure 1: Structure of risperidone. Many methods have been employed for the determination of RSP in biological samples including HPLC with electrochemical detection [2, 3] and RP-HPLC with UV detection [4]. The most extensively used technique for its determination is LC-MS/MS, but several procedures using this technique are confined to biological fluids like human plasma [5–8], plasma and urine [9], and serum [10]. A limited number of analytical methods for the quantitative estimation of RSP in pharmaceutical samples are known. Procedures based on high-performance liquid chromatography and thin-layer densitometric methods [11], spectrophotometry
References
[1]
European Pharmacopoeia, vol. 1, 5th edition, 2005.
[2]
I. Grabnar, A. Mrhar, and I. Locatelli, “Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 50, no. 5, pp. 905–910, 2009.
[3]
K. M. Kirschbaum, S. Finger, F. Vogel et al., “LC with column-switching and spectrophotometric detection for determination of risperidone and 9-hydroxyrisperidone in human serum,” Chromatographia, vol. 67, no. 3-4, pp. 321–324, 2008.
[4]
A. Avenoso, G. Facciolà, M. Salemi, and E. Spina, “Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection,” Journal of Chromatography B, vol. 746, no. 2, pp. 173–181, 2000.
[5]
X. Zhang, X. Zhao, C. Zhang et al., “Accuracy profile theory for the validation of an LC-MS-MS method for the determination of risperidone and 9-hydroxyrisperidone in human plasma,” Chromatographia, vol. 71, no. 11-12, pp. 1015–1023, 2010.
[6]
B. ?abovska, S. L. Cox, and A. A. Vinks, “Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS,” Journal of Chromatography B, vol. 852, no. 1-2, pp. 497–504, 2007.
[7]
C. Kousoulos, Y. Dotsikas, and Y. L. Loukas, “Turbulent flow and ternary column-switching on-line clean-up system for high-throughput quantification of risperidone and its main metabolite in plasma by LC-MS/MS. Application to a bioequivalence study,” Talanta, vol. 72, no. 2, pp. 360–367, 2007.
[8]
J. Bhatt, G. Subbaiah, and S. Singh, “Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma,” Rapid Communications in Mass Spectrometry, vol. 20, no. 14, pp. 2109–2114, 2006.
[9]
M. De Meulder, B. M. M. Remmerie, R. de Vries et al., “Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine,” Journal of Chromatography B, vol. 870, no. 1, pp. 8–16, 2008.
[10]
O. V. Olesen and K. Linnet, “Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs,” Journal of Chromatography B, vol. 698, no. 1-2, pp. 209–216, 1997.
[11]
Z. A. El-Sherif, B. El-Zeany, and O. M. El-Houssini, “High performance liquid chromatographic and thin layer densitometric methods for the determination of risperidone in the presence of its degradation products in bulk powder and in tablets,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 5, pp. 975–981, 2005.
[12]
M. S. Kumar, A. A. Smith, G. A. Vasagam, A. K. Muthu, and R. Manavalan, “Development of analytical method for risperidone by UV spectrophotometry,” International Journal of Pharmaceutical Sciences and Research, vol. 1, pp. 122–126, 2010.
[13]
W. E. S. Hassan, “Extractive colorimetric method for the determination of dothiepin hydrochloride and risperidone in pure and in dosage forms,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 8, pp. 1092–1096, 2008.
[14]
J. Schuberth, “Volatile organic compounds determined in pharmaceutical products by full evaporation technique and capillary gas chromatography/ ion-trap detection,” Analytical Chemistry, vol. 68, no. 8, pp. 1317–1320, 1996.
[15]
W. C. Vosburgh and G. R. Cooper, “Complex ions. I. The identification of complex ions in solution by spectrophoto-metric measurements,” Journal of the American Chemical Society, vol. 63, no. 2, pp. 437–442, 1941.
[16]
M. E. Abdel-Hamid, M. A. Abdel-Salam, M. S. Mahrous, and M. M. Abdel-Khalek, “Utility of 7,7,8,8,-tetracyanoquinodimethane and p-chloranilic acid in the qualitative and quantitative analysis of pentazocine,” Journal de Pharmacie de Belgique, vol. 40, no. 4, pp. 237–243, 1985.
[17]
International Conference On Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R 1), Complementary Guideline on Methodology, dated 06 November 1996, incorporated in November 2005, London, UK.